Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
August 10, 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem CEO Issues Shareholder Update on Clinical Programs
July 21, 2020 07:10 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
June 11, 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
June 03, 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
Collaboration will enable Pluristem to develop new technologies relying on its PLX platformThe consortium is supported by the Israeli Innovation Authority as part of its Bio-Convergence Program, and...
Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
May 14, 2020 08:00 ET
|
Pluristem Therapeutics, Inc.
87.5% survival rate of patients on invasive mechanical ventilation injected with PLX cells75% of patients no longer in need of any mechanical ventilation 62.5% of the patients discharged alive from...
U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
May 08, 2020 06:00 ET
|
Pluristem Therapeutics, Inc.
140 patients with severe COVID-19 and ARDS to be treatedPrimary endpoint: ventilator free days during the main 28-day study period, secondary endpoint includes survival rate and ICU free days HAIFA,...
Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
May 05, 2020 09:56 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
April 30, 2020 09:30 ET
|
Pluristem Therapeutics, Inc.
• Elaborating on agreement terms and tranches schedule• Provides update on cash position and clinical program HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
April 30, 2020 02:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- European Investment Bank (EIB) backs Pluristem with €50 million of financing, which will help the company to advance the clinical...
The European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online Signing Ceremony on April 30, 2020
April 27, 2020 06:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, April 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...